<h4>Objective</h4>The optimal first-line immunotherapy regimen for patients with PD-L1 expression ≥50% in squamous non-small cell lung cancer (Sq-NSCLC) remains uncertain. This evidence concerns the gene CD274 and non-small cell lung carcinoma.